THIO Sequenced With Cemiplimab in Advanced NSCLC
← catalyst calendarNCT05208944 · readout in 406 d
Sponsored by Maia Biotechnology (industry) · MAIA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
227estimated
Sites
35
Countries
Australia, Bulgaria, Hungary +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-08 | actual | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: 6-Thio-2'-Deoxyguanosine — also filed as 6-thio-dG, THIO
- Drug: Cemiplimab — also filed as LIBTAYO®
Primary outcomes
what the primary-completion date above is the date OFTo determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
measured Up to 2 years
To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
measured Up to 2 years
To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
measured Up to 2 years
To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
measured Up to 2 years
To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
measured Up to 2 years
Permalink · MAIA's whole pipeline · Catalyst calendar · Every registered study · What changed